title: Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.
abstract: Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer. The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.
authors.affiliation: University of Pittsburgh Cancer Institute, PA, USA.
authors.forename: Shelley
authors.initials: S
authors.lastname: Dranko
authors.forename: Connie
authors.initials: C
authors.lastname: Kinney
authors.forename: Ramesh K
authors.initials: RK
authors.lastname: Ramanathan
mesh_terms: D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005123:Eye / Q000187:drug effects*; D005128:Eye Diseases / Q000139:chemically induced*; D005260:Female; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab